Tempest Therapeutics
TPST
28 hedge funds and large institutions have $3.94M invested in Tempest Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
17% more funds holding
Funds holding: 24 → 28 (+4)
0.12% more ownership
Funds ownership: 0.74% → 0.86% (+0.12%)
16% less capital invested
Capital invested by funds: $4.7M → $3.94M (-$758K)
28% less call options, than puts
Call options by funds: $117K | Put options by funds: $163K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
+$859K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$104K |
| 3 |
FW
FullCircle Wealth
Dallas,
Texas
|
+$97.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$71.3K |
| 5 |
Morgan Stanley
New York
|
+$58.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$145K |
| 2 |
VF
Virtu Financial
New York
|
-$136K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$54.9K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$12.6K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$9.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $8.45K | +$9.48K | +463 | +46,300% |
|
|
PA
27
Parallel Advisors
San Francisco,
California
| $330 | – | – | – |
|
28
CIBC Private Wealth Group
Atlanta,
Georgia
| $186 | – | – | – |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$145K | -7,095 | Closed |
|
|
VF
30
Virtu Financial
New York
| – | -$136K | -4,771 | Closed |
|
|
31
Dimensional Fund Advisors
Austin,
Texas
| – | -$54.9K | -1,930 | Closed |
|
32
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$59 | -2 | Closed |
|
TPST Hedge Fund Activity: Q3 2024 in Review
28 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q3 2024, worth a combined $3.94M — down 16% from $4.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new TPST positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Altium Capital Management, opening a new position worth an estimated $859K. The largest seller was Citadel Advisors, exiting entirely with an estimated $145K sold.
- 28 institutional investors held Tempest Therapeutics (TPST) as of Q3 2024, up from 24 in Q2 2024.
- Funds reported $3.94M of Tempest Therapeutics stock for Q3 2024, down 16% quarter-over-quarter.
- 8 funds opened new Tempest Therapeutics positions in Q3 2024 and 4 closed out, a net change of +4 holders.
- The largest Tempest Therapeutics buyer in Q3 2024 was Altium Capital Management, an estimated $859K added.
- The largest Tempest Therapeutics seller in Q3 2024 was Citadel Advisors, an estimated $145K sold.
Based on aggregated 13F filings for Q3 2024.